Back

Quantification of circulating tumor DNA using deep learning

Jacobsen Skanderup, A.; Zhu, G.; Rahman, C.; Getty, V.; Baruah, P.; Carrie, H.; Lim, A.; Guo, Y. A.; Poh, Z.; Sim, N.; Abdelmoneim, A.; Cai, Y.; Ho, D.; Thangaraju, S.; Poon, P.; Lau, Y.; Gan, A.; Ng, S.; Odinokov, D.; Koo, S.-L.; Chong, D.; Tay, B.; Tan, T.; Yap, Y.; Chok, A.; Ng, M.; Tan, P.; Tan, D.; Wong, L.; Wong, P.; Tan, I.

2023-07-28 bioinformatics
10.1101/2023.07.28.550922 bioRxiv
Show abstract

Quantification of circulating tumor DNA (ctDNA) levels in blood enables non-invasive surveillance of cancer progression. Fragle is an ultra-fast deep learning-based method for ctDNA quantification directly from cell-free DNA fragment length profiles. We developed Fragle using low-pass whole genome sequence (lpWGS) data from multiple cancer types and healthy control cohorts, demonstrating high accuracy, and improved lower limit of detection in independent cohorts as compared to existing tumor-naive methods. Uniquely, Fragle is also compatible with targeted sequencing data, exhibiting high accuracy across both research and commercial targeted gene panels. We used this method to study longitudinal plasma samples from colorectal cancer patients, identifying strong concordance of ctDNA dynamics and treatment response. Furthermore, prediction of minimal residual disease in resected lung cancer patients demonstrated significant risk stratification beyond a tumor-naive gene panel. Overall, Fragle is a versatile, fast, and accurate method for ctDNA quantification with potential for broad clinical utility.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.